Key Takeaways
- • TA Associates will take a majority stake in MedEnvision, a Belgian medtech company whose Efficient Surgery (ESY) solution standardises hip, knee and shoulder replacement procedures, according to a Business Wire release.
- • Financial terms of the transaction were not disclosed, and closing is expected in the fourth quarter of 2026, subject to closing conditions.
- • Founders, CEO Dries Goyens, management and existing financial partner Smile Invest remain fully committed alongside TA.
- • Proceeds-backed growth priorities include further penetration of the US market, international expansion across 26+ countries, a broader product portfolio and a larger commercial organisation.
- • Trent Law advised MedEnvision and its shareholders; Goodwin Law, Stibbe and PwC advised TA.
Summary
TA Associates, a global private equity firm, has agreed to invest in MedEnvision in a transaction that will see TA take a majority stake, alongside the company's founders, management and existing financial partner Smile Invest, according to a Business Wire announcement issued from London. Financial terms were not disclosed. The transaction is expected to close in the fourth quarter of 2026, subject to closing conditions.
MedEnvision, founded in 2012 and headquartered in Westerlo, Belgium, with a US subsidiary, develops medtech solutions that help orthopaedic surgical teams operate more efficiently. Its Efficient Surgery (ESY) solution, built around the Gripper and EsySuit products, standardises key steps of hip, knee and shoulder replacement procedures. The company says the platform helps hospitals reduce procedural costs, free up scarce medical staff, improve ergonomics and support infection control. Its solutions are used in more than 26 countries and sold through a sales team, distributors and agents.
The investment is intended to support long-term growth centred on international expansion, a broader product portfolio and a stronger commercial organisation. MedEnvision said it views TA as a strategic partner and expects TA's healthcare and orthopaedic expertise to support a greater focus on the fast-growing US market. CEO Dries Goyens said the deal reflects recognition of the team's work and that the company will continue its growth path with Smile Invest.
Birker Bahnsen, Managing Director and Head of TA's European Healthcare Investment Team, said TA was impressed by the company's clinically driven innovation and international traction. Bart Cauberghe and Nicolas Costers of Smile Invest said the firm had supported the founders and management team since 2024, a period in which MedEnvision strengthened its international footprint and professionalised its organisation.
According to the release, Trent Law advised MedEnvision and its shareholders, while Goodwin Law, Stibbe and PwC advised TA. TA describes itself as having invested in more than 560 companies since 1968 and having raised $65 billion in capital to date. Smile Invest, a European evergreen investor with over €500m in assets under management, has supported 23 portfolio companies since its 2017 inception.
MedEnvision, founded in 2012 and headquartered in Westerlo, Belgium, with a US subsidiary, develops medtech solutions that help orthopaedic surgical teams operate more efficiently. Its Efficient Surgery (ESY) solution, built around the Gripper and EsySuit products, standardises key steps of hip, knee and shoulder replacement procedures. The company says the platform helps hospitals reduce procedural costs, free up scarce medical staff, improve ergonomics and support infection control. Its solutions are used in more than 26 countries and sold through a sales team, distributors and agents.
The investment is intended to support long-term growth centred on international expansion, a broader product portfolio and a stronger commercial organisation. MedEnvision said it views TA as a strategic partner and expects TA's healthcare and orthopaedic expertise to support a greater focus on the fast-growing US market. CEO Dries Goyens said the deal reflects recognition of the team's work and that the company will continue its growth path with Smile Invest.
Birker Bahnsen, Managing Director and Head of TA's European Healthcare Investment Team, said TA was impressed by the company's clinically driven innovation and international traction. Bart Cauberghe and Nicolas Costers of Smile Invest said the firm had supported the founders and management team since 2024, a period in which MedEnvision strengthened its international footprint and professionalised its organisation.
According to the release, Trent Law advised MedEnvision and its shareholders, while Goodwin Law, Stibbe and PwC advised TA. TA describes itself as having invested in more than 560 companies since 1968 and having raised $65 billion in capital to date. Smile Invest, a European evergreen investor with over €500m in assets under management, has supported 23 portfolio companies since its 2017 inception.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.